Induction of immunogenicity by live attenuated Leishmania donovani centrin deleted parasites in dogs

Vaccine

Volumn 31, Issue 14, 2013, Pages 1785-1792

  Fiuza, Jacqueline Araújo ^a,b,c   Santiago, Helton da Costa ^b   Selvapandiyan, Angamuthu ^d   Gannavaram, Sreenivas ^c   Ricci, Natasha Delaqua ^b   Bueno, Lilian Lacerda ^b   Bartholomeu, Daniella Castanheira ^b   Correa Oliveira, Rodrigo ^a   Nakhasi, Hira Lal ^c   Fujiwara, Ricardo Toshio ^a,b  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^c CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^d Institute of Molecular Medicine   (India)

Author keywords

Attenuated parasite; Canine visceral leishmaniasis; Vaccine

Indexed keywords

CENTRIN; GAMMA INTERFERON; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; INTERLEUKIN 12; INTERLEUKIN 4; LEISHMANIA VACCINE; LEISHMUNE; LIVE ATTENUATED CENTRIN DELETED LEISHMANIA DONOVANI VACCINE; LIVE VACCINE; RECOMBINANT VACCINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DOG; FEMALE; GENE DELETION; IMMUNOGENICITY; IMMUNOGLOBULIN PRODUCTION; INFECTION CONTROL; LEISHMANIA DONOVANI; LYMPHOCYTE PROLIFERATION; MALE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; VACCINATION; VISCERAL LEISHMANIASIS;

ANIMALS; B-LYMPHOCYTES; CALCIUM-BINDING PROTEINS; CHROMOSOMAL PROTEINS, NON-HISTONE; CYTOKINES; DOG DISEASES; DOGS; LEISHMANIA DONOVANI; LEISHMANIASIS VACCINES; LEISHMANIASIS, VISCERAL; T-LYMPHOCYTES; VACCINES, ATTENUATED; VACCINES, SYNTHETIC;

EID: 84875241248     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.01.048     Document Type: Article

References (54)

1. Desjeux P. Leishmaniasis: current situation and new perspectives. Comp Immunol Microbiol Infect Dis 2004, 27(5):305-318.
2. Courtenay O., Quinnell R.J., Garcez L.M., Shaw J.J., Dye C. Infectiousness in a cohort of brazilian dogs: why culling fails to control visceral leishmaniasis in areas of high transmission. J Infect Dis 2002, 186(9):1314-1320.
3. Werneck G.L., Costa C.H.N., Walker A.M., David J.R., Wand M., Maguire J.H. Multilevel modelling of the incidence of visceral leishmaniasis in Teresina, Brazil. Epidemiol Infect 2007, 135(2):195-201.
4. Ashford R.W. The leishmaniases as emerging and reemerging zoonoses. Int J Parasitol 2000, 30(12-13):1269-1281.
5. Schantz P.M., Steurer F.J., Duprey Z.H., Kurpel K.P., Barr S.C., Jackson J.E., et al. Autochthonous visceral leishmaniasis in dogs in North America. J Am Vet Med Assoc 2005, 226(8):1316-1322.
6. Shaw S.E., Langton D.A., Hillman T.J. Canine leishmaniosis in the United Kingdom: a zoonotic disease waiting for a vector?. Vet Parasitol 2009, 163(4):281-285.
7. DesjeuxF P. Leishmaniasis. Public health aspects and control. Clin Dermatol 1996, 14(5):417-423.
8. Palatnik-de-Sousa C.B., dos Santos W.R., Franca-Silva J.C., da Costa R.T., Reis A.B., Palatnik M., et al. Impact of canine control on the epidemiology of canine and human visceral leishmaniasis in Brazil. Am J Trop Med Hyg 2001, 65(5):510-517.
9. Jeronimo S.M., Teixeira M.J., Sousa A., Thielking P., Pearson R.D., Evans T.G. Natural history of Leishmania (Leishmania) chagasi infection in Northeastern Brazil: long-term follow-up. Clin Infect Dis 2000, 30(3):608-609.
10. Magalhaes P.A., Mayrink W., da Costa C.A., Melo M.N., Dias M., Batista S.M., et al. Calazar na zona do Rio Doce - Minas Gerais. Resultados de medidas profilaticas. Rev Inst Med Trop Sao Paulo 1980, 22(4):197-202.
11. Courtenay O., Kovacic V., Gomes P.A.F., Garcez L.M., Quinnell R.J. A long-lasting topical deltamethrin treatment to protect dogs against visceral leishmaniasis. Med Vet Entomol 2009, 23(3):245-256.
12. Gramiccia M., Gradoni L. The current status of zoonotic leishmaniases and approaches to disease control. Int J Parasitol 2005, 35(11-12):1169-1180.
13. Tesh R.B. Control of zoonotic visceral leishmaniasis: is it time to change strategies?. Am J Trop Med Hyg 1995, 52(3):287-292.
14. Baneth G., Shaw S.E. Chemotherapy of canine leishmaniosis. Vet Parasitol 2002, 106(4):315-324.
15. Dye C. The logic of visceral leishmaniasis control. Am J Trop Med Hyg 1996, 55(2):125-130.
16. Ravindran R., Ali N. Progress in vaccine research and possible effector mechanisms in visceral leishmaniasis. Curr Mol Med 2004, 4(6):697-709.
17. Selvapandiyan A., Dey R., Gannavaram S., Lakhal-Naouar I., Duncan R., Salotra P., et al. Immunity to visceral leishmaniasis using genetically defined live-attenuated parasites. J Trop Med 2012, 631460.
18. Selvapandiyan A., Dey R., Nylen S., Duncan R., Sacks D., Nakhasi H.L. Intracellular replication-deficient Leishmania donovani induces long lasting protective immunity against visceral leishmaniasis. J Immunol 2009, 183(3):1813-1820.
19. Silvestre R., Cordeiro-da-Silva A., Ouaissi A. Live attenuated Leishmania vaccines: a potential strategic alternative. Arch Immunol Ther Exp (Warsz) 2008, 56(2):123-126.
20. Selvapandiyan A., Duncan R., Debrabant A., Lee N., Sreenivas G., Salotra P., et al. Genetically modified live attenuated parasites as vaccines for leishmaniasis. Indian J Med Res 2006, 123(3):455-466.
21. Selvapandiyan A., Debrabant A., Duncan R., Muller J., Salotra P., Sreenivas G., et al. Centrin gene disruption impairs stage-specific basal body duplication and cell cycle progression in Leishmania. J Biol Chem 2004, 279(24):25703-25710.
22. Reis A.B., Teixeira-Carvalho A., Giunchetti R.C., Guerra L.L., Carvalho M.G., Mayrink W., et al. Phenotypic features of circulating leucocytes as immunological markers for clinical status and bone marrow parasite density in dogs naturally infected by Leishmania chagasi. Clin Exp Immunol 2006, 146(2):303-311.
23. Fiuza J.A., Fujiwara R.T., Gomes J.A.S., Rocha M.Od.C., Chaves A.T., de Araujo F.F., et al. Profile of central and effector memory T cells in the progression of chronic human chagas disease. PLoS Negl Trop Dis 2009, 3(9):e512.
24. Giunchetti R.C., Reis A.B., da Silveira-Lemos D., Martins-Filho O.A., Correa-Oliveira R., Bethony J., et al. Antigenicity of a whole parasite vaccine as promising candidate against canine leishmaniasis. Res Vet Sci 2008, 85(1):106-112.
25. Campi-Azevedo A.C., Gazzinelli G., Bottazzi M.E., Teixeira-Carvalho A., Correa-Oliveira R., Caldas I.R. In vitro cultured peripheral blood mononuclear cells from patients with chronic schistosomiasis mansoni show immunomodulation of cyclin D1,2,3 in the presence of soluble egg antigens. Microbes Infect 2007, 9(12-13):1493-1499.
26. Fujiwara R.T., Vale A.M., Franca da Silva J.C., da Costa R.T., Quetz J.S., Martins Filho O.A. Immunogenicity in dogs of three recombinant antigens (TSA, LeIF and LmSTI1) potential vaccine candidates for canine visceral leishmaniasis. Vet Res 2005, 36(5-6):827-838.
27. Borja-Cabrera G.P., Santos F.N., Bauer F.S., Parra L.E., Menz I., Morgado A.A., et al. Immunogenicity assay of the Leishmune vaccine against canine visceral leishmaniasis in Brazil. Vaccine 2008, 26(39):4991-4997.
28. Rafati S., Nakhaee A., Taheri T., Taslimi Y., Darabi H., Eravani D., et al. Protective vaccination against experimental canine visceral leishmaniasis using a combination of DNA and protein immunization with cysteine proteinases type I and II of L. infantum. Vaccine 2005, 23(28):3716-3725.
29. Ramiro M.J., Zarate J.J., Hanke T., Rodriguez D., Rodriguez J.R., Esteban M., et al. Protection in dogs against visceral leishmaniasis caused by Leishmania infantum is achieved by immunization with a heterologous prime-boost regime using DNA and vaccinia recombinant vectors expressing LACK. Vaccine 2003, 21(19-20):2474-2484.
30. Rodriguez-Cortes A., Ojeda A., Lopez-Fuertes L., Timon M., Altet L., Solano-Gallego L., et al. Vaccination with plasmid DNA encoding KMPII, TRYP, LACK and GP63 does not protect dogs against Leishmania infantum experimental challenge. Vaccine 2007, 25(46):7962-7971.
31. Fernandes A.P., Costa M.M.S., Coelho E.A.F., Michalick M.S.M., de Freitas E., Melo M.N., et al. Protective immunity against challenge with Leishmania (Leishmania) chagasi in beagle dogs vaccinated with recombinant A2 protein. Vaccine 2008, 26(46):5888-5895.
32. Giunchetti R.C., Correa-Oliveira R., Martins-Filho O.A., Teixeira-Carvalho A., Roatt B.M., de Oliveira Aguiar-Soares R.D., et al. Immunogenicity of a killed Leishmania vaccine with saponin adjuvant in dogs. Vaccine 2007, 25(44):7674-7686.
33. Lemesre J.-L., Holzmuller P., Cavaleyra M., Goncalves R.B., Hottin G., Papierok G. Protection against experimental visceral leishmaniasis infection in dogs immunized with purified excreted secreted antigens of Leishmania infantum promastigotes. Vaccine 2005, 23(22):2825-2840.
34. Giunchetti R.C., Correa-Oliveira R., Martins-Filho O.A., Teixeira-Carvalho A., Roatt B.M., de Oliveira Aguiar-Soares R.D., et al. A killed Leishmania vaccine with sand fly saliva extract and saponin adjuvant displays immunogenicity in dogs. Vaccine 2008, 26(5):623-638.
35. Araujo M.S.S., de Andrade R.A., Sathler-Avelar R., Teixeira-Carvalho A., Andrade M.C., Vianna L.R., et al. T-cell-derived cytokines, nitric oxide production by peripheral blood monocytes and seric anti-Leishmania (Leishmania) chagasi IgG subclass patterns following immunization against canine visceral leishmaniasis using Leishvaccine and Leishmune. Vaccine 2009, 27(7):1008-1017.
36. Palatnik-de-Sousa C.B., Barbosa A.F., Oliveira S.M., Nico D., Bernardo R.R., Santos W.R., et al. FML vaccine against canine visceral leishmaniasis: from second-generation to synthetic vaccine. Expert Rev Vaccines 2008, 7(6):833-851.
37. Onyalo J.A., Mwala D.M., Anjili C.O., Orago A.S., Tonui W.K. Vaccinations with live-attenuated Leishmania major promastigotes and challenge infection with L major in BALB/c mice. East Afr Med J 2005, 82(4):193-197.
38. Kharazmi A., Kemp K., Ismail A., Gasim S., Gaafar A., Kurtzhals J.A., et al. T-cell response in human leishmaniasis. Immunol Lett 1999, 65(1-2):105-108.
39. Reed S.G., Scott P. T-cell and cytokine responses in leishmaniasis. Curr Opin Immunol 1993, 5(4):524-531.
40. Lasri S., Sahibi H., Sadak A., Jaffe C.L., Rhalem A. Immune responses in vaccinated dogs with autoclaved Leishmania major promastigotes. Vet Res 1999, 30(5):441-449.
41. Araujo M.S.S., de Andrade R.A., Sathler-Avelar R., Magalhaes C.P., Carvalho A.T., Andrade M.C., et al. Immunological changes in canine peripheral blood leukocytes triggered by immunization with first or second generation vaccines against canine visceral leishmaniasis. Vet Immunol Immunopathol 2011, 141(1-2):64-75.
42. Stager S., Rafati S. CD8(+) T cells in leishmania infections: friends or foes?. Front Immunol 2012, 3:5.
43. Kaye P.M., Cooke A., Lund T., Wattie M., Blackwell J.M. Altered course of visceral leishmaniasis in mice expressing transgenic I-E molecules. Eur J Immunol 1992, 22(2):357-364.
44. Polley R., Stager S., Prickett S., Maroof A., Zubairi S., Smith D.F., et al. Adoptive immunotherapy against experimental visceral leishmaniasis with CD8+ T cells requires the presence of cognate antigen. Infect Immun 2006, 74(1):773-776.
45. Joshi T., Rodriguez S., Perovic V., Cockburn I.A., Stager S. B7-H1 blockade increases survival of dysfunctional CD8(+) T cells and confers protection against Leishmania donovani infections. PLoS Pathog 2009, 5(5):e1000431.
46. Bhaumik S.K., Naskar K., De T. Complete protection against experimental visceral leishmaniasis with complete soluble antigen from attenuated Leishmania donovani promastigotes involves Th1-immunity and down-regulation of IL-10. Eur J Immunol 2009, 39(8):2146-2160.
47. Mazumder S., Maji M., Ali N. Potentiating effects of MPL on DSPC bearing cationic liposomes promote recombinant GP63 vaccine efficacy: high immunogenicity and protection. PLoS Negl Trop Dis 2011, 5(12):e1429.
48. Skeiky Y.A., Kennedy M., Kaufman D., Borges M.M., Guderian J.A., Scholler J.K., et al. LeIF: a recombinant Leishmania protein that induces an IL-12-mediated Th1 cytokine profile. J Immunol 1998, 161(11):6171-6179.
49. Macatonia S.E., Hsieh C.S., Murphy K.M., O'Garra A. Dendritic cells and macrophages are required for Th1 development of CD4+ T cells from alpha beta TCR transgenic mice: IL-12 substitution for macrophages to stimulate IFN-gamma production is IFN-gamma-dependent. Int Immunol 1993, 5(9):1119-1128.
50. Seder R.A., Gazzinelli R., Sher A., Paul W.E. Interleukin 12 acts directly on CD4+ T cells to enhance priming for interferon gamma production and diminishes interleukin 4 inhibition of such priming. Proc Natl Acad Sci U S A 1993, 90(21):10188-10192.
51. Coler R.N., Reed S.G. Second-generation vaccines against leishmaniasis. Trends Parasitol 2005, 21(5):244-249.
52. Alexander J., Bryson K. T helper (h)1/Th2 and Leishmania: paradox rather than paradigm. Immunol Lett 2005, 99(1):17-23.
53. Kedzierski L., Zhu Y., Handman E. Leishmania vaccines: progress and problems. Parasitology 2006, 133(Suppl.):S87-S112.
54. Roatt B.M., Aguiar-Soares R.D.O., Vitoriano-Souza J., Coura-Vital W., Braga S.L., Correa-Oliveira R., et al. Performance of LBSap vaccine after intradermal challenge with L. infantum and saliva of Lu. longipalpis: immunogenicity and parasitological evaluation. PLoS ONE 2012, 7(11):e49780.